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Abstract
Background
Depression affects 20–30% of HIV-infected patients and is associated with worse HIV out-
comes. Although effective depression treatment is available, depression is largely untreated
or undertreated in this population.
Methods
We quantified gaps in antidepressant treatment, treatment adjustments, and outcomes
among US patients in routine HIV care in the nationally distributed CNICS observational clin-
ical cohort. This cohort combines detailed clinical data with regular, self-reported depressive
severity assessments (Patient Health Questionnaire-9, PHQ-9). We considered whether
participants with likely depression received antidepressants, whether participants on antide-
pressants with persistently high depressive symptoms received timely dose adjustments,
and whether participants achieved depression remission. We considered a cross-sectional
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Results
The cross-sectional sample was 87% male, 53% Caucasian, 25% African American, and
18% Hispanic; the prospective sample was similar. In both samples, 39–44% had likely
depression, with 44–60% of those receiving antidepressants. Of participants receiving anti-
depressants, 20–26% experienced persistently high depressive symptoms; only a small
minority of those received antidepressant dose adjustments. Overall, 35–40% of partici-
pants on antidepressants achieved full depression remission. Remission among partici-
pants with persistently high depressive symptoms was rare regardless of dose adjustments.
Conclusions
In this large, diverse cohort of US patients engaged in routine HIV care, we observed large
gaps in antidepressant treatment, timely dose adjustment to address persistently high
depressive symptoms, and antidepressant treatment outcomes. These results highlight the
importance of more effective pharmacologic depression treatment models for HIV-infected
patients.
Introduction
Depression is a highly prevalent comorbidity among people living with HIV and is associated
with a range of negative clinical outcomes, including reduced antiretroviral treatment (ART)
adherence and increased mortality.[1, 2] Effective depression treatment, potentially in combi-
nation with adherence supports, may be important to improve HIV treatment adherence and
clinical outcomes.[3–5] Yet despite effective pharmacological and psychotherapeutic treat-
ments,[6, 7] depression among HIV-infected individuals often goes unrecognized clinically[8]
and, when recognized, is often not treated.[9, 10] Moreover, the depression treatment that is
provided has rarely been characterized in detail.[11] In particular, to the authors’ knowledge
no prior research among patients engaged in HIV care have distinguished evidence-based
depression treatment from clinical inertia–the failure to initiate or intensify treatment when
indicated on the basis of evidence-based guidelines.[12, 13] For pharmacological treatment, a
core principle of modern evidence-based guidelines involves regular assessment of depressive
symptom response, combined with promptly adjusting doses if depressive symptoms have not
fully resolved.[14, 15]
Characterization of the gaps in depression identification, treatment, treatment adjustments,
and response is central to guide development of mental health services for people living with
HIV. Yet reliable estimates, especially from diverse populations in routine HIV care, are lack-
ing. Here we estimate pharmacologic treatment gaps in a large, diverse multisite cohort of
patients engaged in HIV primary care across the United States. We leverage a unique combi-
nation of detailed antidepressant medication histories and repeated, systematic depressive
severity measures coinciding with HIV primary care appointments to characterize depression,
antidepressant treatment, the extent to which persistently high depressive symptoms were fol-
lowed by antidepressant adjustments, and antidepressant treatment outcomes. Guided by the
conceptual framework described below,[14, 15] we hypothesized that the majority of patients
with an indication for depression treatment would not be receiving pharmacologic treatment,
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the majority of treated patients with a need for antidepressant dose adjustment would not be
receiving adjustments, and the majority of treated patients would not achieve timely depres-
sion remission.
Methods
This study was approved by the Institutional Review Board at the University of North Carolina
at Chapel Hill (IRB number 13–1707).
Conceptual framework
Our approach was guided by the conceptual framework of the depression treatment contin-
uum.[11, 16] Of patients engaged in HIV clinical care who also have depression, a portion are
clinically recognized, a portion of those recognized initiate depression treatment, and a portion
of those treated receive evidence-based treatment (primarily meaning structured psychotherapy
of a given intensity and duration, or antidepressant treatment with careful monitoring and dose
increases to achieve response[14, 15]), with sizeable drop-offs at each stage. While some depres-
sion will remit with only unstructured supportive counseling or low-dose antidepressant pre-
scription, outcomes are expected to be better with evidence-based treatment, particularly given
the primarily chronic nature of depression in the HIV-infected patient population.[17]
Data source
We used the Center for AIDS Research (CFAR) Network of Integrated Clinical Systems
(CNICS) observational cohort. The CNICS cohort includes over 30,000 HIV infected adults in
care since 1995 at eight geographically diverse United States HIV clinical sites.[18] Approxi-
mately 1800 new patients enroll and 13% of existing patients leave the dynamic clinical cohort
each year. Institutional review boards at each CNICS site have approved the study protocols.
The CNICS database captures comprehensive clinical data including standardized diagno-
sis, medication, laboratory, appointment, and demographic information collected through
electronic health records and other institutional data systems. Medication data is based on a
combination of electronic medical records, provider electronic order entry, and pharmacy
databases. Prescription data is rigorously captured within each health system but each site also
has protocols for capturing prescriptions from outside providers, although this data may not
be as comprehensive as prescriptions issued by within-system providers. Data quality proce-
dures have been described in more detail previously.[18] CNICS sites further collect self-
administered socio-behavioral assessments, known as patient-reported outcomes (PROs).
CNICS participants complete computer-based PROs at regular HIV primary care appoint-
ments, typically every 4–6 months.[19, 20] These questionnaires include validated measures of
depression, anxiety, substance use, alcohol use, antiretroviral (ARV) adherence, sexual behav-
ior, physical symptoms, and health-related quality of life. Although several of the CNICS sites
do provide psychosocial services, data on these services is very limited. Data is not systemati-
cally collected on referrals to outside specialty mental health care.
Measures
Depressive symptom severity was measured in the PROs by the Patient Health Questionnaire-
9 (PHQ-9), a widely used screening tool that determines the presence and frequency during
the previous two weeks of the 9 core symptoms of major depressive disorder.[21, 22] A PHQ-9
score10 is generally considered a positive screen for likely major depression.[21, 22] The
PHQ-9 is effective as a longitudinal measure of response to depression treatment, with a score
Depression Treatment Gaps in HIV Care
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<5 among those previously depressed or on depression treatment indicating remission (full
treatment success).[23]
Antidepressant treatment was defined as a prescription for a selective serotonin reuptake
inhibitor (citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline), seroto-
nin–norepinephrine reuptake inhibitor (desvenlafaxine, duloxetine, venlafaxine), or other
second-generation antidepressant (bupropion, mirtazapine, nefazadone). Tricyclics alone (pri-
marily amitriptyline in this sample) were not considered antidepressant treatment, as amitrip-
tyline is often prescribed for pain relief in this population and tricyclics are uncommonly used
currently as antidepressants. Tricyclic use was rare (<4% of person-time) in the analysis sam-
ple and half of tricyclic prescriptions were below minimally therapeutic doses for depression
(e.g.25mg daily of amitriptyline). Similarly, sleep agents alone (primarily trazodone in this
sample) were not considered antidepressant treatment.
To characterize antidepressant treatment as evidence-based or not, we compared PHQ-9
scores and treatment decisions over time (Fig 1), capitalizing on the unique combination of
longitudinal PHQ-9 measures and detailed medication histories. Evidence-based guidelines
for antidepressant monitoring suggest that if significant depressive symptoms remain after
4–6 weeks on a given dose, the dose should be increased within the FDA-approved range if
the medication is being tolerated.[14, 15] Therefore, if a PHQ-9 measure following antidepres-
sant initiation was10 and a treatment adjustment (dose increase or switch or addition of
antidepressant) was subsequently made, we classified the period from the treatment adjust-
ment to the next PHQ-9 measure as an episode of evidence-based antidepressant treatment
(Fig 1, Type 3; pharmacologic adjustment). If no treatment adjustment was made, we classified
the period as pharmacologic inertia, or the failure to make a change in antidepressant dose as
suggested by evidence-based guidelines for pharmacologic depression treatment (Type 4If the
PHQ-9 measure was<10 (meaning no treatment adjustment was indicated according to
guidelines), the period until the next PHQ-9 was classified as evidence-based antidepressant
treatment regardless of whether treatment adjustments occurred (Type 2; pharmacologic
maintenance (no adjustment indicated)). The period from antidepressant initiation to the first
Fig 1. Conceptual framework for classification of antidepressant treatment decisions.
doi:10.1371/journal.pone.0166435.g001
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follow-up PHQ-9 was classified separately as an initial treatment period (Type 1; pharmaco-
logic treatment initiation).
Statistical analysis
We considered two different perspectives: cross-sectional, representing the status of the active
clinic patient population at a point in time; and prospective, representing the experience of a
cohort of patients establishing care at CNICS sites.
Cross-sectional. Here, we restricted our attention to an 18-month period, July 2011-
December 2012, during which time PRO collection was well established at 6 of 8 CNICS sites
(Fenway Community Health Center-Harvard University; University of Alabama-Birmingham;
University of California-San Diego; University of California-San Francisco; University of
North Carolina-Chapel Hill; and University of Washington). For each PHQ-9 measure in this
window we included the six following person-months in the analysis sample; one participant
could have multiple PHQ-9s. For each person-month, we defined an indication for depression
treatment as either a recent (within 6 months) PHQ-9 score10 or a current antidepressant
prescription. We defined antidepressant treatment as a current antidepressant prescription.
We defined evidence-based antidepressant depression treatment as detailed above. We defined
remission of depression as a PHQ-9 score<5 among those currently on antidepressant treat-
ment.[23] We defined mild and high depressive symptoms as PHQ-9 scores of 5–9 and10,
respectively. We calculated the proportion of person-time meeting each definition to estimate
period-prevalence of each characteristic.
Prospective. Here, we followed forward in time all participants newly establishing HIV
care at a CNICS site after that site’s launch of PROs (ranging from 2005–2012). While all par-
ticipants were new to care at CNICS sites, information was not always available on whether
they were entirely new to HIV care or were transferring care. We defined time to indication for
depression treatment as the time from entry to either (a) first PHQ-910 or (b) antidepressant
prescription. We defined time to antidepressant treatment as the time from entry to antidepres-
sant prescription. We defined time to remission as the time from the first PHQ-910 to the
first subsequent PHQ-9 <5. Kaplan-Meier survival and failure functions for each of these end-
points were calculated, and the cumulative proportion “failing” (meeting criteria for depres-
sion, starting antidepressant treatment, achieving remission) was estimated at 12 months.
Participants were censored after 12 months without an HIV medical appointment (lost to
care) or at the site’s most recent CNICS data upload (administrative censoring). Using non-
parametric Kaplan-Meier functions, we compared time to antidepressant treatment between
person-time following a recent high PHQ-9 (10), following a recent low PHQ-9 (<10), or
with no recent PHQ-9, with “recent” defined as within 6 months. In these comparisons, PHQ-
9 status was treated as a time-varying characteristic: a participant’s person-time could be allo-
cated to one or more of these categories over follow-up. Similarly, we compared time to remis-
sion between person-time receiving and not receiving antidepressant treatment.
To compare remission as a function of evidence-based antidepressant treatment vs. phar-
macologic inertia, we divided each participant’s person-time treated with antidepressants into
sequential “episodes” demarcated by each follow-up PHQ-9 measure, with each episode classi-
fied as one of Types 1–4 as defined above. We calculated the probability that episodes of each
type ended with remission (PHQ-9<5). Episodes >1 year (i.e., no follow-up PHQ-9 measure
within 1 year) were excluded. Once a participant had achieved remission, further episodes
were excluded. Probabilities of remission and 95% confidence intervals were estimated using
generalized estimating equations to account for correlation across multiple episodes per
person.
Depression Treatment Gaps in HIV Care
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In sensitivity analyses, we assessed the potential for bias due to non-random attrition in the
prospective sample by applying inverse probability of observation weights based on variables
available at the time of entry to care, including age, sex, race/ethnicity, HIV risk group, CD4
count, and viral load. As most sites do not administer PHQ-9s or other PROs at the first visit,
these variables were not included in the weights. Results from weighted models were compared
to results from the primary complete case analysis. Potential heterogeneity of estimates across
sites was assessed with likelihood ratio tests comparing primary models to models that
included a set of indicator terms for sites.
All analyses were conducted in Stata version 13 (College Station, Texas).
Results
Cross-sectional
Sample. Between July 2011-December 2012, 6,219 participants contributed 57,837 per-
son-months of observation (mean [standard deviation]: 9.3 [5.1] per person) (Table 1). Most
participants were male (87.2%) and the mean age was 45.3 (10.3) years. Over half of the partici-
pants were Caucasian (53%), a quarter were African-American (25%), and the majority of
remaining participants were Hispanic (18%). Two-thirds were men who reported having sex
with other men (MSM).
Depression treatment continuum. Across sites, 39% of person-time had an indication
for depression treatment while 61% did not (Fig 2). For 16% of person-time, patients had a
Table 1. Description of sample.
Mean (SD) or n (%)
Cross-sectional Prospective
Participants 6219 (100) 2936 (100)
Person-time per participant, mo. 9.3 (5.1) 29.6 (19.5)
Age, years 45.3 (10.3) 41.9 (10.9)
Current gender
Male 5420 (87) 2575 (88)
Female 799 (13) 360 (12)
Transgendered 48 (1) 19 (1)
Race / ethnicity
Caucasian non-Hispanic 3281 (53) 1465 (51)
African American non-Hispanic 1558 (25) 742 (26)
Hispanic 1097 (18) 538 (19)
Other 239 (4) 137 (5)
HIV transmission risk category
Heterosexual sex 1161 (20) 381 (14)
MSM 3894 (65) 1843 (65)
IDU 819 (14) 538 (19)
Other 96 (2) 59 (2)
Site
Site A 536 (9) 254 (9)
Site B 1655 (27) 753 (26)
Site C 101 (2) 3 (0)
Site D 2186 (35) 1135 (39)
Site E 819 (13) 89 (3)
Site F 922 (15) 702 (24)
doi:10.1371/journal.pone.0166435.t001
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PHQ-9 score10 and were not receiving antidepressants; for 9% of person-time, patients had
a PHQ-9 score10 and were receiving antidepressants; for 6% of person-time, patients had
mild depressive symptoms (PHQ-9 score 5–9) while receiving antidepressants; and for 8% of
person-time, patients were receiving antidepressants and were in remission (PHQ-9 score
<5). Thus, of all patients with an indication for depression treatment, 60% were receiving anti-
depressant treatment, and of patients receiving treatment, 36% were in remission.
One-fifth of treated person-time (22%) was immediately following antidepressant initiation
(Type 1) (Table 2). For half (52%) of treated person-time, no treatment adjustment was indi-
cated because the patient was partially or fully responding to treatment (Type 2, pharmaco-
logic maintenance (no adjustment indicated)). For the remaining one quarter (26%) of treated
person-time, a treatment adjustment was indicated by ongoing high depressive symptoms; in
about one-fifth of these cases (6% overall), a treatment adjustment was actually made (Type 3,
pharmacologic adjustment), while in about four-fifths (20% overall) no treatment adjustment
was made (Type 4, pharmacologic inertia).
Combining these estimates indicates that 39% (95% CI: 39–40%) of the population had an
indication for depression treatment, 24% (23–24%) were receiving antidepressant treatment,
18% (17–18%) were receiving evidence-based antidepressant treatment (either through passive
pharmacologic maintenance or active pharmacologic adjustment), and 9% (9–10%) had
achieved remission after starting pharmacologic treatment (Fig 3).
Prospective approach
Sample. After the site-specific launch of PHQ-9 screening, 2,936 participants establishing
HIV care contributed 86,906 person-months of observation (mean [SD}: 29.6 [19.5] per
Fig 2. Distribution of depression and antidepressant treatment status across CNICS sites.
doi:10.1371/journal.pone.0166435.g002
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person) (Table 1). Demographic characteristics were similar to those of participants in the
cross-sectional approach.
Depression treatment continuum. Among all participants new to CNICS care, the
Kaplan-Meier failure function estimate of the proportion having an indication for depression
Table 2. Antidepressant treatment, treatment adjustments, and remission.
Distribution of person-time, % Probability of remission, %
Cross-sectional (4,831 PYO) Prospective (7,240 PYO) Prob (95% CI) (n/N)
No antidepressant treatment 76 79 n/a
Any antidepressant treatment 24 21 n/a
SSRI* 16 14 n/a
SNRI* 3 2 n/a
Other second-generation agent* 8 7 n/a
Multiple antidepressants* 4 3 n/a
Antidepressant treatment classification**
Type 1, pharmacologic treatmentinitiation 22 58 23 (18–28) (52/230)
Type 2, pharmacologic maintenance 52 21 29 (18–40) (16/66)
Type 3, pharmacologic adjustment 6 5 0 (0–12) (0/28)
Type 4, pharmacologic inertia 20 15 9 (2–16) (4/68)
PYO: Person-years of observation. SSRI: Selective serotonin reuptake inhibitor. SNRI: Serotonin-norepinephrine reuptake inhibitor.
* Not mutually exclusive
** See Fig 1 legend
doi:10.1371/journal.pone.0166435.t002
Fig 3. The depression treatment continuum for patients engaged in HIV primary care.
doi:10.1371/journal.pone.0166435.g003
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treatment within the first 12 months of establishing HIV care at a CNICS site was 44%. The
estimated probability of starting an antidepressant within the first 12 months of care was 44%
in person-time following a PHQ-9 score10, 17% in person-time following a PHQ-9 score
<10, and 30% in person-time not immediately following a PHQ-9 screening. Among partici-
pants who had not started antidepressants at the time of PHQ-9 screening, the probability of
achieving remission within 12 months of a PHQ-9 score10 was 36% overall, 34% in person-
time following antidepressant initiation, and 39% in person-time not following antidepressant
initiation.
When considering evidence-based antidepressant treatment versus pharmacologic inertia,
over half (58%) of the treated person-time was before the first follow-up PHQ-9 (Type 1; phar-
macologic treatment initiation) (Table 2). Approximately one-fifth (21%) of person-time fol-
lowed a PHQ-9 score <10, when no treatment adjustment would be indicated (Type 2,
pharmacologic maintenance (no adjustment indicated). The remaining 20% of person-time
followed a PHQ-9 score10, when a treatment adjustment would be indicated; in approxi-
mately one-quarter of cases, or 5% overall, a pharmacologic adjustment was made (Type 3,
pharmacologic adjustment) whereas in three-quarters of cases, or 15% overall, no treatment
adjustment was made (Type 4, pharmacologic inertia). The probability of remission at the end
of the initial treatment period (Type 1) was 23% (95% CI: 18–28%) and at the end of pharma-
cologic maintenance episodes where no adjustment was indicated (Type 2) was 29% (95% CI:
18–40%). At the end of the 28 episodes of evidence based antidepressant treatment where
pharmacologic adjustment was made (Type 3), there were no instances of remission (0%;
exact 95% CI: 0–12%) and at the end of the 68 episodes of pharmacologic inertia (Type 4), the
probability of remission was 9% (2–16%).
Combining these estimates indicates that 44% (42–46%) of the population had an indica-
tion for depression treatment in the first 12 months of CNICS care, 19% (17–22%) received
any antidepressant treatment in the first 12 months, 12% (11–14%) were receiving evidence-
based antidepressant treatment (either through passive pharmacologic maintenance or active
pharmacologic adjustment), and 7% (6–8%) achieved remission within 12 months (Fig 3).
There was notable variation in the cascade parameters across sites: the proportion having an
indication for depression treatment ranged from 37–46%, the proportion receiving any antide-
pressant ranged from 14–30%, the proportion receiving evidence-based treatment ranged
from 6–20%, and the proportion achieving remission ranged from 2–9%.
In sensitivity analyses to assess the role of non-random attrition, estimates of the depression
treatment continuum (Fig 3) and the probability of remission (Table 2) were virtually un-
changed when inverse probability of observation weights were applied.
Discussion
This analysis represents the first comprehensive assessment of the depression treatment con-
tinuum in a large, diverse sample of US patients engaged in HIV primary care. We identified
substantial gaps in pharmacologic depression treatment, antidepressant adjustments, and
remission in this population. Regardless of whether we considered a cross-section of all active
clinic patients or a prospective cohort of patients establishing care, approximately 2 in 5
patients were in need of depression treatment, about half of those in need received antidepres-
sant treatment, and fewer than half of those on antidepressant treatment achieved full depres-
sion remission.
Approximately 40% of CNICS patients had an indication for depression treatment. This
estimate is consistent with other reports of depression prevalence among HIV-infected
patients in similar primary care populations.[10, 24–32] Of the patients in our analyses who
Depression Treatment Gaps in HIV Care
PLOS ONE | DOI:10.1371/journal.pone.0166435 January 26, 2017 9 / 14
had an indication for depression treatment, the probability of receiving antidepressants was
43% among patients newly establishing care, and 60% in our cross-sectional analysis. These
estimates are generally comparable to those from similar settings, in which the prevalence of
antidepressant treatment among HIV-infected patients has ranged from 40–49%.[9, 10, 33, 34]
The combination in the CNICS cohort of repeated depressive severity assessments at clini-
cal contacts paired with detailed antidepressant medication histories provided a unique oppor-
tunity to evaluate antidepressant treatment adjustments in this population. We assessed the
frequency with which patients on antidepressant treatment but with persistently high depres-
sive symptoms received dose adjustments as indicated by evidence-based guidelines.[12, 13]
While we estimated that more than half of treated person-time was evidence-based antidepres-
sant treatment, in the vast majority of cases this was because the patient had no or mild depres-
sive symptoms and no treatment adjustment was indicated Of the patients who required active
evidence-based antidepressant treatment (Types 3 and 4) because of persistent high depressive
symptoms, only one in four received a pharmacologic treatment adjustment. Importantly, the
database does not identify the prescriber; some antidepressants may have been prescribed by a
psychiatrist rather than the HIV provider. Nevertheless, this result suggests that prescribers for
these patients may be comfortable with initiating antidepressant medications but may not
titrate when the depressive illness fails to respond to an initial dose. Care models that support
primary care physicians in prescribing antidepressants may be necessary to address this gap.
[35–37]
Among the small number of patients in our analysis who required and received antidepres-
sant treatment adjustment, none achieved remission; among patients who required treatment
adjustment and did not receive it, remission rates were not much different. In contrast, about
a quarter of patients achieved remission within the initial antidepressant treatment period,
and of patients exhibiting mild remaining depressive symptoms while on treatment, about a
quarter went on to achieve remission. In addition, after a high PHQ-9, the overall remission
rates between patients starting and not starting antidepressant treatment were quite similar.
These findings suggest two separate depression phenotypes- one that responds promptly to
antidepressant treatment, and may even resolve in the absence of treatment (for example,
newly diagnosed patients in whom high depressive symptoms may reflect short-term adjust-
ment disorder rather than a major depressive episode), and one that is treatment-resistant
regardless of antidepressant treatment adjustments. These phenotypes would almost certainly
be associated with a range of covariates including medical and psychiatric comorbidities and
psychosocial factors. It is possible for example that the patients who received treatment adjust-
ments were those with psychiatric complexity or otherwise known to be treatment-resistant
and were referred to psychiatric resources. These patients would have been less likely to
achieve remission due to their depression phenotype, a type of confounding by indication, per-
haps explaining why none of the patients who received Type 3 treatment achieved remission.
The limitations of this study should be considered. First, depression and remission are
defined based on a screening instrument that, while possessing excellent psychometric proper-
ties, is not diagnostic. To benchmark the performance of the PHQ-9 screening tool in this
study relative to other populations, our results can be compared to data from the STARD ran-
domized controlled trial in which the QIDS-SR16, a screening tool with similar properties to
the PHQ-9, was used to assess depression in a large non-HIV infected outpatient sample.[38]
In that study the depression remission rate was 36% after initial treatment initiation, compared
to 23% in the analogous time period in the current study. This comparison of two large popu-
lations in which depression was measured with similar self-report screening tools suggests that
there may be a lower remission rate in this HIV-infected cohort compared to non-HIV
infected outpatient populations. Second, the measure of pharmacologic depression treatment
Depression Treatment Gaps in HIV Care
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used in these analyses was imperfect for several reasons. We made the assumption that patients
obtained and were adherent with antidepressant medications as they were prescribed. As pre-
scription uptake and adherence would be less than 100%, treatment was likely overestimated,
although providers’ clinical decisions were accurately captured. Third, these data do not pro-
vide information about the reasons why some patients with persistent high depressive symp-
toms did not receive a dose adjustment. For example, a dose adjustment may have been
suggested by the provider but declined by the patient. The provider may not have been aware
of the PHQ-9 result (although the PHQ-9 score as a measure of the patient’s depressive sever-
ity on that day is nonetheless valid). Similarly, the provider may have based a dosing decision
on other factors gathered during the clinical encounter not captured by the PHQ-9. Impor-
tantly, we focused specifically on pharmacological treatment of depression; other important
and effective depression treatments, particularly evidence-based psychotherapy, were not
included in this analysis. In this regard treatment may have been underestimated if a large pro-
portion of the study population engaged in psychotherapeutic treatment. While many Type 4
episodes in this analysis may be non-evidence based treatment periods, in that patients need-
ing a pharmacologic treatment adjustment did not receive a dose adjustment, we cannot draw
definitive conclusions about the proportion of these episodes that represent true gaps in
depression treatment without information on other modalities of depression treatment such
as psychotherapy. Fourth, estimates may be biased due to non-random attrition. While analy-
ses accounting for possible differential attrition by demographic and clinical variables were
nearly identical to primary analyses, we did not have measures of depressive severity at entry
to care for most patients. If patients with depression at entry were most likely to be lost to care
before completing a PHQ-9, our estimates of depression prevalence would be biased down-
ward. Finally, while CNICS contains comprehensive medication information from within
each site’s health system, and all sites have clinical protocols that include capturing prescrip-
tions from outside providers during clinic appointments, prescriptions by outside providers
may still be under-represented in the database.
Another important consideration is the irregular timing and spacing of depressive severity
and remission measures used in our analyses. In a real-world outpatient psychiatric setting,
depressive severity is ideally measured within 4–6 weeks of initiating antidepressant treatment
and appropriate changes to the treatment regimen are made. In this study we did not have
such frequent measures of depression so we considered severity and remission assessments up
to 6 months after antidepressant initiation. While our results provide important aggregate
parameters of the pharmacologic depression treatment continuum within the HIV clinical set-
ting, estimates of remission may not reflect the detailed course of illness assessed in psychiatric
care settings. However, our findings may be highly germane to the provision of pharmacologic
depression treatment in outpatient HIV care settings.
A key strength of this study is the size, diversity, and richness of the data source. The
CNICS cohort is distinct from many other longitudinal HIV cohorts in that it is a clinical care
cohort: participation requires only consent to have routinely collected medical data captured,
leading to very high participation rates across all sites. With inclusion of medical centers in the
West, South, mid-Atlantic, and Northeast, the relevance of the experiences of the CNICS
cohort to patients engaged in HIV primary care across the US is high. At the same time
CNICS is distinct from many administrative databases in its inclusion of a range of validated
self-reported behavioral assessments that have been integrated into routine clinical care, per-
mitting investigations such as the current one that require measures of depressive severity
linked in time to clinical actions. It is important to note that CNICS sites have established
rapid clinical assessment and response protocols for patients indicating suicidality on the
PROs, which may have led to better depression identification and treatment in the CNICS
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cohort than would have been present without the PROs. One interesting observation from the
present analysis was the range in depression treatment and outcome indicators across sites.
Although it was beyond the scope of this analysis to explore reasons for this heterogeneity,
such differences could be due to differences in care practices or differences in patient popula-
tions (e.g. insurance coverage or cultural attitudes towards antidepressant prescription).
This study suggests substantial gaps across the steps of the depression treatment continuum
among patients in HIV primary care settings across the United States and provides the first
estimates of evidence-based antidepressant treatment delivery in these settings. Our findings
show that successful pharmacologic treatment of depression is uncommon among patients
with HIV infection, with small proportions of depressed patients receiving antidepressant
dose adjustments when indicated or achieving remission. With increasing emphasis on decen-
tralizing depression care from specialty mental health settings into primary care, including
HIV primary care, HIV providers may need improved support in recognizing and treating
depression, particularly in cases that require titrating or changing antidepressant treatment
regimens. Collaborative care models that address these gaps in pharmacologic depression
treatment could play an important role in addressing the burden of depression among patients
with HIV infection.
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